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This study evaluated the acceptability of a supportive model of follow- up. One hun-
dred and twelve women recovering from breast cancer were randomised to receive 
standard breast clinic aftercare (Control n = 56) or on demand by open access after-
care by breast care nurses (Intervention n = 56). Participants attended a support- based 
psycho- educational programme delivered in four half- day group sessions. Three qual-
ity of life questionnaires (EORTC QLQ- C30, QLQ- BR23, HADS) were administered at 
baseline and 6- monthly intervals for 2 years. Multilevel linear regression modelling 
methods were used for evaluation. Age was found to be a statistically significant pre-
dictor of quality of life in several sub- scales. Increasing age was negatively associated 
with sexual functioning, systematic therapy side effects and physical functioning, and 
positively associated with future perspective. Aftercare assignment was not found to 
be a statistically significant predictor. Women treated for early breast cancer were not 
disadvantaged by allocation to the open access supportive care model in terms of 
quality of life experienced. The model for follow- up was demonstrated to be a feasible 
alternative to routinised hospital- based follow- up and adds to the evidence for strati-
fied follow- up for low- risk cancer patients, incorporating self- management education. 
Stratified follow- up pathways are viewed as a preferable approach.
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1  | INTRODUCTION
The main purpose of routine follow- up care, after potentially curative 
treatment for early breast cancer, is to monitor for local recurrence, 
manage the late effects of treatment and provide information, sup-
port and reassurance for patients. In the past, many women treated 
for breast cancer received hospital follow- up for life. At the time of the 
study current practice across the Yorkshire Cancer Network, UK was 
to provide follow- up for 5 years after completion of primary therapy; 
women may attend from 7 to 17 appointments over this period. The 
value of this resource intensive practice has been questioned for many 
years (Beaver & Luker, 2005; Gulliford, Opomu, Wilson, Hanham, & 
Epstein, 1997; Moschetti, Cinuini, Lambertini, Levaggi, & Liberati, 
2016; Taggart, Donnelly, & Dunn, 2012). It had been acknowledged 
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that routine hospital visits of asymptomatic breast cancer patients 
can be stressful to patients and serve no clinical benefit, apart from 
providing a platform for annual mammography (Puglisi et al., 2014). 
Symptoms attributable to local recurrence are more commonly iden-
tified by the patient in the interval between clinic visits (Montgomery, 
2009), or in general practice (Moschetti et al., 2016). Yet, the prac-
tice of regular follow- up in breast clinics of essentially well women 
had become an entrenched practice in the UK contributing to health 
service burden and potentially lengthening waiting times for new re-
ferrals. Follow- up in breast cancer care was addressed in the National 
Institute for Clinical Guidelines (NICE, 2009) for Early and Locally 
Advanced Breast Cancer: Diagnosis and Treatment with the recom-
mendation that follow- up after treatment should be discussed with 
patients and an agreed care plan documented. The guideline proposed 
that mammograms should be offered annually for 5 years and then 
every 3 years after the age of 50 as part of the national screening pro-
gramme. NICE (2009) indicated clinical follow- up could be provided by 
primary, secondary or through shared care. This guideline was a major 
breakthrough that added further weight to the growing belief amongst 
health care practitioners that routine hospital follow- up failed to meet 
the self- management and informational needs of all breast cancer pa-
tients (NCSI, 2013; NICE, 2009).
The value of routine hospital follow- up as medical surveillance 
with the primary objective of finding and treating local recurrence or 
new breast cancers was questioned unsurprisingly given the lack of 
evidence of significantly improved survival outcomes or palliation as 
a result of early detection of metastatic disease. The lifetime risk of 
local recurrence in a previously treated breast with low- risk disease 
has been reported as 1% at Year 1 increasing to 5% at Years 3 and 
4 (Wheeler, Stenning, Negus, Picken, & Metcalfe, 1999). This indi-
cated that intensive early follow- up provided little clinical gain as few 
women were likely to relapse within this time period. Clinical examina-
tion has been shown to detect relatively few relapses in the conserved 
breast and had a lower sensitivity than mammography (Geurts et al., 
2012). However, the risk of contra- lateral breast cancer was 3–5 times 
greater than that of the general population risk of developing a breast 
cancer. These risks endorse the need for some form of surveillance to 
detect and treat the disease before survival is compromised.
Interestingly, the majority of local recurrences, interval cancer, 
identified between hospital visits are detected by women themselves 
(Churn & Kelly, 2001; Jack, Kerr, & Kunkler, 1998). Unsurprisingly, 
studies have demonstrated that many patients are willing, and often 
do, take responsibility for seeking medical attention in the event of 
symptoms (Gulliford et al., 1997; O’Mahony, Hegarty, & McCarthy, 
2011).
From the perspective of the healthcare professional, women who 
have had breast cancer are primarily concerned about recurrence, yet 
many may have information and support needs that coexist (Armes 
et al., 2009; Elliott et al., 2011; Khan, Mant, Carpenter, Forman, & 
Rose, 2011), which should to be addressed as well. Armes et al. (2009) 
reported that after 6 months, 20% of women have five or more unmet 
needs, and these were frequently the fear of recurrence and psycho-
logical in nature. There is evidence that patients want access to advice 
about any symptoms or concerns, preferably from a clinician they 
know (Durif- Bruckert et al., 2015). Patients experiencing symptoms 
necessitating urgent assessment and/or treatment should also have 
access to systems providing rapid access to specialist breast and on-
cology services. Specialist nurses, skilled in providing information and 
support, have successfully provided telephone follow- up services for 
cancer patients and provided triage to assess and manage new symp-
toms (Cox & Wilson, 2003; Koinberg, Fridlund, Engholm, & Holmberg, 
2004). More recently Shewbridge et al. (2014) have evaluated the de-
livery of a nurse- led end of treatment consultation clinic for women 
who have completed treatment for early breast cancer. This reported 
favourable outcomes for nurses in developing new consultation skills 
and confidence in addressing previously unmet patient needs and pa-
tient acceptability.
Some women access support beyond the scope of NHS provision, 
e.g. complementary therapies or peer support from other patients. 
National cancer charities, such as Breast Cancer Care and Macmillan 
Cancer Support are also providing well- received information and 
support services to aid self- management (Breast Cancer Care, 2011; 
Scanlon, Reed, Wray, & Fenlon, 2011; Scanlon & Tilki, 2006) and po-
tentially could be more formally incorporated as co- partners in pro-
viding a “Recovery Package”, as recommended by the National Cancer 
Survivorship Initiative (NCSI) and endorsed by government policy. The 
most recent national cancer strategy Independent Cancer Taskforce, 
(Cancer Research UK, 2015) identified the need for NHS service pro-
viders to provide cancer patients with easier access to information, 
both during and post- treatment, about what support is available to 
them.
Follow- up is also intended to provide psychological assessment 
and support for women recovering from breast cancer as psycholog-
ical morbidities, such as anxiety and depression, are common in this 
patient group. Clinic attendances have been associated with increased 
anxiety as for some it revisits the feelings engendered during diagno-
sis and enhance concerns about the threat of recurrence particularly 
if they share a waiting room with women with active and advanced 
disease (King, Brooks, Featherstone, & Topping, 2014). Health reas-
surance is commonly offered as the main benefit that patients derive 
from check- ups but for anxious patients this may be counterproduc-
tive (Stark et al., 2004).
The goal of many patients is to get “back to normal” as soon as 
possible after their cancer treatment but Harvey (2009), a clinical psy-
chologist who has a wealth of experience working with people who 
have cancer, believes a period of recuperation, convalescence and re-
habilitation is needed first. He postulates that “normal” life is not the 
same as it was before the cancer diagnosis and those patients need 
to learn new skills to help them cope with the changes. The acquisi-
tion of these skills could be facilitated by attendance on a structured 
psycho- educational self- management programme in the company of 
other women at a similar stage of their treatment. Breast Cancer Care 
has experience of running “Moving Forward” courses, which aim to 
educate women about their illness and related effects, in addition to 
learning self- management skills. The need for reassurance and psy-
chological support forms a key element in these courses.
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Many clinicians recognise the shortfalls of current services, but 
are reluctant to reduce follow- up to less than 5 years. Various rea-
sons have been given such as the re- structuring challenges required 
to transition to routine mammography only service for this breast 
cancer population including clinician resistance. Follow- up care 
is essentially screening (Moschetti et al., 2016), while offering the 
opportunity to monitor patients undergoing Tamoxifen treatment 
(currently 5 years), and initiate change speedily if current practice 
changes, and/or new endocrine therapies are recommended. Other 
less resource intensive approaches for monitoring would seem rea-
sonable given the availability and acceptability of specialist nurses, 
information technology and telephony systems to support and man-
age recall for routine screening and trigger alerts to patients and gen-
eral practice should recommendations regarding adjuvant hormonal 
therapies change.
There is no evidence of a preference for intensive or minimalist 
follow- up among well- informed women. Patients in trials comparing 
different types of follow- up tend to express satisfaction with their 
allocation model. Likewise, there is limited evidence regarding uni-
versal patient preference for involvement in decision- making about 
treatments (Collins, Bekker, & Dodwell, 2004) although studies have 
found that patients with increased involvement in decision- making 
about follow- up care reported better quality of life (Andersen, Bowen, 
Morea, Stein, & Baker, 2009; Andersen & Urban, 1999). Fallowfield’s 
(2001) work in this area indicated that it is more important for patients 
to understand and participate in the clinician’s decision- making pro-
cess than to make treatment decisions themselves. This concurs with 
the NICE guidelines that recommend that the patient and specialist 
should agree a written, follow- up care plan together as part of a holis-
tic needs assessment and care plan, and that locally agreed measures 
should be developed to support the woman’s transition from the unit 
(NCSI, 2010).
Risk of recurrence is associated with the stage of disease at diag-
nosis. According to the All Breast Cancer Report (Cheung et al., 2009), 
64% of the 28,462 invasive breast cancers diagnosed in the UK were 
Stage I (17%) or Stage II (47%). These groups had 5- year survival rates 
of 99% and 90% respectively. Follow- up practice could be stratified 
according to individual risk. Moreover, it would not seem unreason-
able to offer women with low risk, early- stage disease alternative 
models of follow- up whilst reserving hospital follow- up for high- risk 
patients. It is within this context that a model of follow- up based on 
promoting a supportive, open access, self- management approach to 
follow- up care was developed with regard to previous work on pa-
tients’ views and needs.
2  | METHODS
2.1 | Aim and design
The aim of the study was to test the acceptability of an open access sup-
portive care model of follow- up for women with early, low- risk breast 
cancer, with an embedded psycho- educational self- management 
programme (Moving Forward). A longitudinal single- centre, open 
randomised controlled design was used to measure and detect trends 
of quality of life indicators.
2.2 | Sample and setting
Women newly diagnosed with AJCC Stage 1 or Stage 2 breast cancer, 
treated with curative intent and considered to be clinically at low risk 
of recurrence were invited to participate in the study. Potential partic-
ipants were recruited by a breast cancer nurse following surgery and 
staging and where possible prior to any planned radiotherapy treat-
ment. Women were excluded from the study if they: had Stage 3 or 
4 breast cancer; were receiving or received adjuvant chemotherapy; 
were identified by the multidisciplinary team as requiring follow- up 
due to increased risk factors such as young age, had significant family 
history or bilateral cancers; or were taking part in breast cancer clinical 
trials that required follow- up as per trial protocol. Informed consent 
was obtained from all individual participants included in the study.
Eligible women were invited to attend a psycho- educational self- 
management programme designed by the UK charity Breast Cancer 
Care called “Living with Breast Cancer” (now known as “Moving 
Forward”). This comprised half- day sessions delivered over four con-
secutive weeks and addressed topics that included the management 
of breast cancer, the impact of breast cancer, breast reconstruction, 
lymphoedema, exercise, breast awareness after surgery, healthy eating 
and the management of menopausal symptoms. The programme was 
originally designed for breast cancer survivors with the aim of enhanc-
ing health literacy and self- confidence, supporting self- management 
and reducing isolation. Following attendance on the course, women 
were randomised into one of two groups: (1) standard hospital after- 
care (Control Group) and (2) open access after- care (Intervention 
Group). As a result of the nature of the intervention, it was not possible 
to blind participants to the type of after- care received.
Women in the Intervention Group were not routinely followed- up. 
They were provided with a resource pack designed to complement the 
course and details of how to access breast surgical services through a 
telephone helpline run by breast cancer nurses should they experience 
any breast cancer related concerns.
When following the open access supportive model of follow- up, 
patients are under the care of the consultant for the usual duration 
of appointment times. In this setting, it was for 5 years. During this 
time, if concerned or worried, a patient can return to the clinic im-
mediately without a GP referral. Diagnostic investigations can be 
booked and problems resolved sooner through reducing stressful 
waiting times and starting further treatment, if required, with mini-
mal delay. The open access supportive model recognises that the role 
of the breast cancer nurse has extended to an advanced practitioner, 
able to instigate investigations and complete breast examinations 
and biopsies. GPs are informed that their patient has attended the 
course and are informed how the open appointments system works. 
Any further communications with the patient is communicated to the 
GPs. The patient will have mammography annually for 5 years and 
receive the results through the post and their GPs will receive a copy 
of the report.
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2.3 | Ethics statement
All procedures performed in this study involving human participants 
were in accordance with the ethical standards of the national research 
committee and with the 1964 Declaration of Helsinki and its later 
amendments or comparable ethical standards. The study protocol 
was approved by the national and local ethics and research panels. 
Informed consent was obtained from all individual participants in-
cluded in the study.
There is no conflict of interest linked to any of the authors associ-
ated with this study. The research has been conducted to benefit the 
lives of breast cancer survivors, without any financial benefit to the 
authors.
2.4 | Data collection
Three Quality of Life questionnaires: EORTC Quality of Life QLQ- 
C30 (Aaronson et al., 1993) and EORTC QLQ- BR23 (Sprangers 
et al., 1996); and the Hospital Anxiety and Depression Scale (HADS) 
(Zigmond & Snaith, 1983) were administered to each participant at 
baseline (T:0), 6 (T:1), 12 (T:2), 18 (T:3) and 24 months (T:4). The first 
five questions on the QLQ- BR23 questionnaire were not relevant to 
the current analysis and responses to these questions were not elic-
ited from participants.
2.5 | Analysis
The questionnaires were scored according to the QLQ and HADS 
scoring manuals (Fayers, Aaronson, Bjordal, Curran, & Bottomley, 
2001). The QLQ- C30 questionnaire generates scores in the follow-
ing Functional scales: Global health status (QL2), Physical functioning 
(PF2), Role functioning (RF2), Emotional functioning (EF), Cognitive func-
tioning (CF) and Social functioning (SF); and in the following Symptom 
scales: Fatigue (FA), Nausea and vomiting (NV), Pain (PA), Dyspnoea 
(DY), Insomnia (SL), Appetite loss (AP), Constipation (CO), Diarrhoea 
(DI) and Financial difficulties (FI). In this questionnaire, high scores 
of the Functional sub- scales represent higher levels of functioning; 
and low score on the Symptom sub- scales represent higher level of 
functioning.
The QLQ- BR23 questionnaire generates scores in the following 
Functional scales: Body image (BRBI), Sexual functioning (BRSEF), Sexual 
enjoyment (BRSEE) and Future perspective (BRFU); and in the following 
Symptom scales: Systematic therapy side effects (BRST), Breast symp-
toms (BRBS) and Arm symptoms (BRAS). The additional symptom scale 
of Upset by hair loss (BRHL) generated by the BR23 questionnaire was 
not considered in the current analysis, as it was based on questions in 
the BR23 to which responses had not been elicited. In this question-
naire, high scores of the Functional sub- scales represent higher levels 
of functioning; and low score on the Symptom sub- scales represent 
higher level of functioning.
The HADS questionnaire generated scores for the characteristics 
of Anxiety and Depression. In this questionnaire, low scores on both 
these sub- scales represent higher levels of functioning.
A small proportion of questions on all three questionnaires were 
left unanswered. Data imputation was undertaken following recom-
mended methods in the questionnaire scoring manuals; hence mean 
values were imputed for missing values in scales in which a response 
was recorded from at least half of the items. Other missing values were 
not imputed.
Descriptive statistics (means and standard deviations) were cal-
culated for all sub- scales considered, and sub- scale scores were in-
spected individually for the presence of trends.
A multilevel model formulation was utilised to indicate relation-
ships between variables of interest to allow for variation in trends over 
time between different individuals. This model facilitates appropriate 
treatment of variables at both patient- and measurement-levels.
A total of eight series of models, both univariate and multivariate, 
were derived. For the HADS scale, a series of multivariate models was 
derived, using the scores on the Depression and Anxiety sub- scales 
of the HADS instrument. For the QLQ- BR23 questionnaire, a signifi-
cantly lower number of responses were received on the BRSEF and 
BRSEE sub- scales, which could not be imputed. Inclusion of these 
scale scores as response variables may have compromised the accu-
racy of a multivariate model considering responses arising from all 
functional sub- scales. Hence, these sub- scales were analysed individ-
ually as a series of univariate models. The remaining functional sub- 
scales in the QLQ- BR23 questionnaire, BRBI and BRFU, were analysed 
as a series of multivariate models. The three symptom sub- scales in 
the BR23 questionnaire were analysed together as a further series of 
multivariate models.
The Global Health Status sub- scale was analysed individually as 
a series of univariate models. The 5 functional scales (excluding the 
Global Health Status sub- scale) in the QLQ- C30 questionnaire were 
analysed together as a series of multivariate models. The nine symp-
tom scales in the QLQ- C30 questionnaire were analysed together as a 
further series of multivariate models.
2.6 | Model selection strategy
For each set of outcome measures considered, a total of 5 nested 
models were derived: a null model including only the constant term 
and no explanatory variables; a model additionally including the age 
covariate; a model additionally including the grouping factor; a model 
including both variables and a model including both variables and the 
interaction between them.
For each model, the deviance (likelihood ratio statistic) was de-
termined. A statistically significant reduction in deviance between 
two nested models with degrees of freedom ν1 and ν2, which has an 
approximate χ2 distribution on ν1–ν2 degrees of freedom, was taken 
to be indicative of a parameter which should remain in the model. In 
this way likelihood ratio considerations determined which of the five 
models associated with each set of responses measures provided the 
best summary of the data.
All analyses were performed using the MLwiN software Version 
2.25, using the Iterated Generalised Least Squares (IGLS) procedure 
for parameter estimation.
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3  | RESULTS
3.1 | Descriptive summary of data
One hundred and twelve women aged 29.6–85.9 years at baseline 
(T:0) recovering from breast cancer were recruited to the study. Fifty- 
six participants were randomised to the control group and 56 to the 
intervention group. One participant failed to complete baseline data 
after recruitment. A further 29 individuals were lost to follow- up be-
tween baseline and 24 months; hence, a full set of follow- up data was 
received from 82 patients (73%).
The mean age of patients in the control group at baseline was 
60.5 years (SD = 9.79 years); the mean age of patients in the interven-
tion group at baseline was 60.7 years (SD = 10.86 years). Means and 
standard deviations of transformed scores obtained on all sub- scales 
of all three questionnaires at baseline and 6, 12, 18 and 24 months are 
given in Tables 1–3 below.
No obvious time- dependent trends were observed in either of the 
HADS sub- scales. Scores recorded in the control group were slightly 
higher on the Depression sub- scale than those recorded in the inter-
vention group at most time- points, indicating higher functionality in 
the intervention group with respect to depression. However, scores 
recorded in the control group were slightly lower on the Anxiety sub- 
scale than those recorded in the intervention group at all time- points, 
indicating higher functionality in the control group with respect to 
anxiety. In both cases, the relative month- by- month change, and the 
difference between groups, was small compared with within- patient 
variability.
Variability remained approximately constant in both scales across 
the 24- month period. Considering the 24- month period as a whole, 
functionality declines slightly in both sub- scales, in both control and 
intervention groups.
No obvious time- dependent trends were observed in any of the 
QLQ- BR23 sub- scales, with the exception of the BRBS sub- scale, in 
which a monotonic downward trend (corresponding to continuously 
improving functioning) was shown in both the control and intervention 
groups. Other groups appeared approximately static, with the BRSEE 
scale scores in the control group being completely static. However, in 
the intervention group this sub- scale showed a fall of 16.7 percentage 
points over 24 months.
Variability remained approximately constant in all scales across the 
24- month period. Considering the 24- month period as a whole, im-
proved functionality compared with baseline values was recorded in 
approximately half of the functional and symptom sub- scales consid-
ered, in both control and intervention groups.
No obvious time- dependent trends were observed in any of the 
QLQ- C30 sub- scales. Some sub- scales, such as the DY, AP and CO 
sub- scales exhibited a degree of oscillation in either or both groups. 
Other sub- scales appeared to be fairly static over time, with only 
the FI sub- scale in the intervention group behaving monotonically. 
However, the existence of one monotonic sub- scale in a data set of 
this size would be expected even under the hypothesis of no time- 
dependent trends.
Variability remained approximately constant in all scales across the 
24- month period. Considering the 24- month period as a whole, im-
proved functionality compared with baseline values was recorded in 
just over half of the functional and symptom sub- scales considered, in 
both control and intervention groups.
3.2 | Model selection
Changes in likelihood ratio statistics, plus the assessment of signifi-
cance of the change in these statistics between models, indicated that 
a model which best describes the Depression and Anxiety sub- scales 
of the HADS questionnaire; the BRBI, BRFU, BRSEF, BRST, BRBS and 
BRAS sub- scales of the QLQ- BR23 questionnaire; and PF2, RF2, EF, 
CF and SF sub- scales of the QLQ- C30 questionnaire, would include an 
age factor but not a grouping factor. Such a model cast in a multilevel 
context is given by the expression
where yjk is the score obtained by the k
th patient on the jth measure-
ment occasion; β0jk is a constant including random terms at the patient 
and measurement-levels; and x1jk is the age of the k
th patient at the jth 
measurement occasion.
Neither age nor group were found to significantly improve 
goodness- of- fit in a model which best describes the BRSEE sub- scale 
of the QLQ- BR23 questionnaire; and the G1 sub- scale of the QLQ- 
C30 questionnaire. Such a model cast in a multilevel context is given 
by the expression
where yjk and β0jk are defined as above.
Both age and group, plus the interaction between them, were 
found to significantly improve goodness- of- fit in a model which best 
describes the FA, NV, PA, DY, SL, AP, CO, DI and FI sub- scales of the 
yjk=β0jk+β1x1jk
yjk=β0jk
TABLE  1 HADS questionnaire sub- scale scores (mean [SD]): control and intervention groups
Sub- scale
Control group Intervention group
Baseline
6  
months
12  
months 18 months 24 months Baseline
6  
months
12  
months 18 months 24 months
Depressiona 3.53 (3.45) 3.58 (3.70) 3.59 (4.03) 3.46 (3.18) 3.94 (4.12) 3.19 (2.72) 2.99 (2.89) 3.44 (3.09) 3.73 (3.39) 3.71 (3.24)
Anxietya 5.71 (4.43) 5.53 (4.12) 5.47 (4.80) 5.83 (4.52) 5.74 (5.00) 6.59 (3.42) 6.39 (4.05) 6.32 (3.72) 7.01 (4.21) 7.00 (4.60)
aA low score on this sub- scale represents a higher level of functioning.
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QLQ- C30 questionnaire. Such a model cast in a multilevel context is 
given by the expression
where yjk, β0jk, x1jk are defined as above; x2jk is the group of the k
th 
patient at the jth measurement occasion (patient- level variable); and 
x1jkx2k is the age group interaction.
Age appears in 22 models and aftercare group in nine models. 
Significance levels of 0.00233 for age; and 0.00568 for group corre-
sponded to familywise error rates of 5% in both cases. Under these 
criteria, age is statistically significant with respect to the BRSEF, BRFU 
and BRST sub- scales of the QLQ- BR23 questionnaire; and the PF2 
sub- scale of the QLQ- C30 questionnaire. At best estimate, an increase 
in age of 1 year is associated with: a reduction of 1.01 points on the 
BRSEF sub- scale; an increase of 0.66 points on the BRFU sub- scale; 
a reduction of 0.68 points on the BRST sub- scale and a reduction of 
0.42 points on the PF2 sub- scale.
The aftercare group as a main effect was not statistically signifi-
cant with respect to any sub- scale in which the age·group interaction 
was not included in the final model. The age·group interaction was 
yjk=β0jk+β1x1jk+β2x2k+β12x1jkx2k
TABLE  2 QLQ- BR23 questionnaire sub- scale scores (mean [SD]): control and intervention groups
Sub- 
scale
Control group Intervention group
Baseline
6  
months
12  
months
18  
months
24  
months Baseline
6  
months
12  
months
18  
months
24  
months
BRBIa 75.7 (28.6) 73.8 (31.2) 77.0 (30.3) 79.0 (27.2) 80.4 (26.2) 78.7 (21.1) 82.0 (16.7) 80.5 (20.9) 82.0 (20.3) 79.4 (25.9)
BRSEFa 27.6 (29.0) 23.0 (23.3) 20.7 (24.7) 20.1 (22.0) 18.4 (23.7) 28.0 (26.2) 33.3 (28.5) 24.7 (28.9) 24.7 (28.9) 24.7 (25.0)
BRSEEa 72.7 (25.0) 72.7 (25.0) 72.7 (29.1) 72.7 (32.7) 72.7 (32.7) 77.8 (27.2) 83.3 (18.3) 77.8 (27.2) 66.7 (21.1) 61.1 (25.1)
BRFUa 65.7 (30.3) 57.4 (30.5) 59.3 (28.9) 62.0 (26.6) 58.3 (31.2) 61.5 (24.1) 55.2 (26.2) 57.3 (28.4) 60.4 (29.9) 55.2 (30.1)
BRSTb 28.9 (21.1) 29.6 (23.5) 27.5 (24.6) 25.0 (21.5) 25.5 (22.4) 26.0 (22.1) 22.6 (16.8) 22.4 (18.7) 25.0 (22.2) 26.4 (20.7)
BRBSb 20.9 (18.3) 16.8 (18.9) 15.5 (22.5) 13.4 (16.8) 9.3 (11.2) 23.2 (20.2) 17.2 (14.6) 15.4 (18.1) 12.6 (13.7) 11.5 (12.8)
BRASb 13.3 (18.2) 15.4 (22.7) 14.5 (23.6) 11.1 (16.1) 15.4 (20.8) 14.5 (14.3) 11.8 (15.9) 12.1 (15.3) 10.8 (15.3) 12.0 (15.0)
BRAS, Arm symptoms; BRBI, Body image; BRBS, Breast symptoms; BRFU, Future perspective; BRSEE, Sexual enjoyment; BRSEF, Sexual functioning; BRST, 
Systematic therapy side effects.
aA high score on this sub- scale represents a higher level of functioning.
bA low score on this sub- scale represents a higher level of functioning.
TABLE  3 QLQ- C30 questionnaire sub- scale scores (mean [SD]): control and intervention groups
Sub- 
scale
Control group Intervention group
Baseline 6 months 12 months 18 months 24 months Baseline 6 months
12  
months
18  
months
24  
months
QL2a 72.9 (18.8) 71.4 (22.4) 75.0 (20.3) 71.4 (24.8) 75.0 (19.8) 70.7 (18.1) 74.2 (16.7) 69.4 (21.5) 70.7 (24.0) 69.9 (20.5)
PF2a 86.1 (14.0) 85.4 (17.1) 87.2 (13.0) 86.3 (14.7) 86.1 (15.3) 86.5 (17.5) 86.5 (17.0) 84.7 (17.9) 85.7 (20.7) 86.7 (19.3)
RF2a 78.2 (27.6) 82.4 (29.3) 83.8 (23.4) 81.5 (28.7) 85.6 (23.6) 75.6 (25.8) 88.9 (16.0) 79.4 (21.3) 83.9 (25.3) 82.2 (22.7)
EFa 77.9 (17.7) 78.8 (24.2) 78.3 (25.6) 78.8 (22.5) 75.4 (27.4) 75.8 (17.9) 76.1 (20.4) 77.5 (24.4) 75.5 (22.4) 75.3 (24.8)
CFa 79.5 (24.9) 76.5 (28.5) 79.1 (27.0) 80.3 (20.9) 80.3 (24.4) 78.5 (20.3) 79.6 (20.1) 76.9 (19.6) 78.0 (17.9) 76.9 (21.4)
SFa 82.9 (22.5) 84.6 (23.4) 85.0 (22.6) 87.6 (20.1) 85.5 (21.7) 79.6 (23.8) 90.9 (14.8) 86.6 (21.3) 88.7 (20.8) 86.6 (20.8)
FAb 30.9 (26.9) 32.1 (26.8) 29.3 (30.1) 28.7 (29.4) 30.2 (26.9) 33.0 (17.2) 26.4 (18.9) 25.7 (23.4) 27.2 (24.9) 27.2 (24.6)
NVb 3.8 (8.1) 6.4 (14.1) 2.6 (8.1) 7.7 (18.3) 5.6 (12.9) 4.4 (8.9) 3.3. (9.2) 5.0 (9.9) 8.9 (15.0) 7.8 (16.2)
PAb 18.8 (28.1) 20.1 (25.1) 20.1 (29.4) 23.1 (28.5) 17.9 (27.4) 22.7 (21.6) 18.2 (16.3) 20.2 (25.3) 19.7 (23.0) 15.7 (20.8)
DYb 16.7 (27.0) 19.4 (30.2) 9.3 (17.1) 11.1 (23.9) 14.8 (24.5) 12.6 (20.7) 14.9 (24.5) 14.9 (22.9) 19.5 (26.0) 14.9 (26.1)
SLb 34.3 (33.3) 32.4 (33.3) 34.3 (34.3) 36.1 (33.2) 35.2 (32.8) 34.5 (31.5) 27.6 (25.3) 33.3 (28.2) 33.3 (28.2) 32.2 (28.8)
APb 9.9 (17.3) 5.4 (12.5) 6.3 (13.3) 8.1 (19.9) 7.2 (13.9) 6.7 (16.1) 10.0 (21.7) 7.8 (18.9) 11.1 (22.0) 5.6 (19.7)
COb 14.5 (26.3) 8.5 (23.8) 9.4 (25.3) 11.1 (27.9) 12.8 (26.1) 17.2 (26.2) 9.2 (17.6) 14.9 (26.1) 23.0 (33.5) 18.4 (30.3)
DIb 7.2 (16.0) 8.1 (16.5) 9.9 (22.0) 7.2 (13.9) 10.8 (19.3) 6.7 (16.1) 8.9 (15.0) 7.8 (18.9) 4.4 (11.5) 6.7 (16.1)
FIb 10.3 (25.5) 12.0 (25.9) 7.7 (23.5) 11.1 (25.7) 10.3 (27.7) 13.8 (26.0) 9.2 (26.6) 6.9 (22.5) 6.9 (22.5) 5.7 (21.9)
AP, Appetite loss; CF, Cognitive functioning; CO, Constipation; DI, Diarrhoea; DY, Dyspnoea; EF, Emotional functioning; FA, Fatigue; FI, Financial difficul-
ties; NV, Nausea and vomiting; PA, Pain; PH2, Physical functioning; RF2, Role functioning; SF, Social functioning; SL, Insomnia; QL2, Global health status.
aA high score on this sub- scale represents a higher level of functioning.
bA low score on this sub- scale represents a higher level of functioning.
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statistically significant with respect to the DI sub- scale of the QLQ- 
C30 questionnaire.
For all outcome measures except the NV and DI sub- scales of the 
QLQ- C30 questionnaire, the majority of model variance calculated 
using the variance partition coefficient occurred at the patient level, 
with relatively low variation in scores obtained from the same patient 
on different measurement occasions. These sub- scales were both as-
sociated with very low scores, indicating high functionality. However, 
there is a factor of at least two separating the mean scores on these 
sub- scales recorded at different months.
4  | DISCUSSION
In general, the scores recorded in both groups (Tables 1–3) indicated a 
study population who were generally in good health. Even at baseline, 
at which point it might be expected scores to be at a low point, all the 
functional scales on the C30 questionnaire, plus the BRBI, BRSEE and 
BRFU functional scales on the BR23, were all scored at 65% or above. 
All symptom scores were below 25% at baseline and the scores on 
some sub- scales (DI, AP, NV) were below 10%. Baseline depression 
rates were quite low (mean score of 3.6 of 14), but baseline anxiety 
levels had a mean score of 6.4 out of 14. No significant improvement 
over 2 years from the baseline measurement was recorded in most 
scales (Tables 1–3).
A descriptive assessment of the performance of the intervention 
group versus the control group did not necessarily imply that each 
scale is of equal merit, which may not be the case. For example, it may 
be more important to show better improvement on, say, global health 
than on a scale such as appetite loss.
A clear finding of the results was that very few time- dependent 
trends were observed. Quality of life scores did not change signifi-
cantly over the 24- month follow- up period. The sole time- dependent 
trend, exhibited in both groups by the Breast Symptoms sub- scale 
(Table 1) was not unexpected, considering that the sample comprised 
patients recovering from breast cancer. Furthermore, such an event 
was not statistically unlikely: for 24 such sequences in each of two 
groups, the probability of two or more monotonic sequences is 0.191 
under a null hypothesis of no time- related component.
A notable strength of this longitudinal study was the high retention 
rate, with 82 of 112 patients (73%) followed- up for the full 2- year 
study period. However, those in better health may have been more 
likely to be lost to follow- up at an early stage, possibly because they 
wished to forget about their experience of cancer and move on with 
their lives. A comparison of responses from patients who were subse-
quently lost to follow- up and those who remained on the study until 
the end of the follow- up period did not reveal any obvious systematic 
differences in responses on any sub- scale.
In general, the majority of responses received were valid, and little 
imputation was required. The response rate of questions on the BRSEF 
and BRSEE sub- scales was lower than on other questions, possibly 
being due to the perception that these questions were eliciting private 
information or information irrelevant to the monitoring of recovery 
from breast cancer. A small number of respondents provided unsolic-
ited comments on these sections of their questionnaires to that effect.
One limitation of the study was that demographic, social and co- 
morbidity factors were not recorded on the participants, other than 
age; although effective randomisation of a sample size of 112 should 
remove or reduce the potential for imbalances across groups. However, 
some unsolicited comments provided by respondents on their ques-
tionnaires suggested a belief that their responses were due wholly or 
partly to causes other than breast cancer. For example, a patient in her 
80 s reported fatigue, making an association with her age. Another pa-
tient noted that she was an arthritis sufferer and the progress of this 
ailment was affecting her well- being to a greater extent than the previ-
ous episode of breast cancer. Another participant recorded low overall 
quality life scores and noted that she had recently suffered a family 
bereavement. It is accepted that the internal validity of this study may 
have been limited by the presence of such generally unrecorded factors.
Patient age has been found to be a far more important predictor of 
sub- scale scores than the assigned aftercare group. Age appeared as a 
main effect or as part of an interaction in all models with the exception 
of models using the GF1 and BRSEE outcome measures. The significant 
interaction on the DI sub- scale implies that the effect of aftercare group 
was different for patients of different ages. Among younger patients, 
those in the control group had higher functionality, whereas among 
older patients, those in the intervention group had higher functionality.
There is no evidence that people who have had early breast cancer 
are disadvantaged by the open access, supportive care model in terms 
of quality of life experienced by patients using a variety of quality of 
life indicators. The innovative model for follow- up was evaluated and 
demonstrated as a feasible alternative to hospital- based follow- up, 
which has the added advantage of not having to attend a clinic that 
may reinforce unnecessary worry of recurrence by low- risk patients. 
The pressures in the clinics today are enormous and continue to in-
crease with all new patient referrals. People who have secondary dis-
ease are living longer due to improved treatments and require regular 
clinic appointments, which add to the demand. The open access sup-
portive care model may be viewed as radical in some circles; however, 
this study presents a reasonable case for implementing this approach. 
The results from the pilot study confirmed that this was a robust pro-
gramme of education, fulfilling patients’ needs at this point and in the 
future. Evaluation confirmed that the women were confident with 
their own knowledge and understanding of diagnosis and treatments 
and the potential risks to themselves. They needed to be confident of 
self- care, assessment of themselves and in knowing which health care 
professional should be contacted. Furthermore, the clinicians fully 
supported the course as an acceptable substitute to clinic attendance 
recognising that they cannot provide the same level of support and 
education in a brief clinic visit.
5  | CONCLUSION
Our innovative open access model for follow- up was evaluated 
and demonstrated to be a feasible and acceptable alternative to 
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routinised hospital- based follow- up; it is now embedded in practice 
in the UK through the charity Breast Cancer Care. Our work adds 
to the evidence for stratified follow- up for low- risk cancer patients, 
which includes open access to breast care nurses and patient self- 
management education for patients. Patient initiated access to care 
removed the necessity to attend a hospital- based clinic potentially in-
creasing NHS efficiencies and reducing patient’s unnecessary anxiety 
about recurrence and facilitating better recovery. Stratified follow- up 
pathways based person- centred approaches and holistic supportive 
and wellness care models now form part of the NHS cancer strategy 
(NCSI, 2013; NICE, 2002) and can be viewed as a safe, preferable way 
forward.
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